J P Morgan Chase & Co set a €99.40 ($116.94) price target on Gerresheimer AG (ETR:GXI) in a report issued on Wednesday morning. The firm currently has a buy rating on the stock.

GXI has been the subject of a number of other reports. Credit Suisse Group set a €80.00 ($94.12) price objective on Gerresheimer AG and gave the company a buy rating in a research report on Tuesday. Hauck & Aufhaeuser set a €63.50 ($74.71) price target on Gerresheimer AG and gave the stock a neutral rating in a report on Thursday, September 21st. Goldman Sachs Group, Inc. (The) set a €73.00 ($85.88) price target on Gerresheimer AG and gave the stock a neutral rating in a report on Friday, June 30th. Berenberg Bank set a €75.00 ($88.24) price target on Gerresheimer AG and gave the stock a buy rating in a report on Monday, September 4th. Finally, Commerzbank Ag set a €73.00 ($85.88) price target on Gerresheimer AG and gave the stock a neutral rating in a report on Thursday, July 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. Gerresheimer AG has a consensus rating of Hold and a consensus price target of €73.14 ($86.05).

Gerresheimer AG (ETR GXI) opened at 65.09 on Wednesday. The stock’s 50 day moving average price is €65.02 and its 200-day moving average price is €70.35. The firm has a market capitalization of €2.04 billion and a price-to-earnings ratio of 18.03. Gerresheimer AG has a one year low of €59.97 and a one year high of €79.47.

ILLEGAL ACTIVITY NOTICE: “J P Morgan Chase & Co Analysts Give Gerresheimer AG (GXI) a €99.40 Price Target” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/10/14/j-p-morgan-chase-99-40-price-target.html.

About Gerresheimer AG

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Analyst Recommendations for Gerresheimer AG (ETR:GXI)

Receive News & Stock Ratings for Gerresheimer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer AG and related stocks with our FREE daily email newsletter.